TW214553B - - Google Patents

Download PDF

Info

Publication number
TW214553B
TW214553B TW081102729A TW81102729A TW214553B TW 214553 B TW214553 B TW 214553B TW 081102729 A TW081102729 A TW 081102729A TW 81102729 A TW81102729 A TW 81102729A TW 214553 B TW214553 B TW 214553B
Authority
TW
Taiwan
Prior art keywords
compound
formula
temperature
ministry
range
Prior art date
Application number
TW081102729A
Other languages
English (en)
Chinese (zh)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of TW214553B publication Critical patent/TW214553B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/044—Pyrrole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW081102729A 1991-04-11 1992-04-09 TW214553B (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68377091A 1991-04-11 1991-04-11

Publications (1)

Publication Number Publication Date
TW214553B true TW214553B (enExample) 1993-10-11

Family

ID=24745378

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081102729A TW214553B (enExample) 1991-04-11 1992-04-09

Country Status (14)

Country Link
EP (2) EP0508792A1 (enExample)
JP (1) JPH06503837A (enExample)
CA (1) CA2108146A1 (enExample)
CZ (1) CZ213693A3 (enExample)
FI (1) FI934461A7 (enExample)
HU (1) HUT70187A (enExample)
IE (1) IE921148A1 (enExample)
IL (1) IL101554A0 (enExample)
MX (1) MX9201643A (enExample)
NO (1) NO933611L (enExample)
NZ (1) NZ242294A (enExample)
SK (1) SK108293A3 (enExample)
TW (1) TW214553B (enExample)
WO (1) WO1992018507A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ245203A (en) * 1991-11-29 1997-07-27 Banyu Pharma Co Ltd 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
EP0575955B1 (en) * 1992-06-22 1999-09-15 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
WO1994007895A1 (en) * 1992-09-25 1994-04-14 Schering Corporation Diindolo compounds and pharmaceutical compositions containing them
US5843935A (en) * 1993-12-07 1998-12-01 Eli Lilly And Company Protein kinase C inhibitors
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
KR100340159B1 (ko) * 1993-12-07 2002-11-23 일라이 릴리 앤드 캄파니 단백질키나제c억제제
US5723456A (en) * 1993-12-07 1998-03-03 Eli Lilly & Company Therapeutic treatment for cardiovascular diseases
WO1995022331A1 (en) * 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
WO1997005140A1 (en) * 1995-07-31 1997-02-13 Novartis Ag Trindene compounds
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
FR2826653B1 (fr) * 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TW201041580A (en) 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
ES2375565T3 (es) 2003-08-07 2012-03-02 Healor Ltd. Composiciones farmacéuticas y métodos para acelerar la cicatrización de heridas.
WO2007026356A2 (en) 2005-08-29 2007-03-08 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
EP2181999A1 (en) 2008-11-03 2010-05-05 Zentiva, A.S. Method of manufacturing ruboxistarin
EP2599494A1 (en) 2010-01-11 2013-06-05 Healor Ltd. PKC inhibitors for the treatment of inflammatory disease or disorder
JP2017524739A (ja) 2014-07-17 2017-08-31 アンセルムInserm 神経筋接合部関連疾患の処置方法
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007045A1 (fr) * 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derives de la substance physiologiquement active k-252
DE3924538A1 (de) * 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung

Also Published As

Publication number Publication date
JPH06503837A (ja) 1994-04-28
NO933611D0 (no) 1993-10-08
FI934461A0 (fi) 1993-10-11
SK108293A3 (en) 1994-09-07
FI934461L (fi) 1993-10-11
EP0508792A1 (en) 1992-10-14
HUT70187A (en) 1995-09-28
AU1798292A (en) 1992-11-17
NO933611L (no) 1993-10-08
IL101554A0 (en) 1992-12-30
MX9201643A (es) 1992-10-01
CA2108146A1 (en) 1992-10-12
NZ242294A (en) 1993-07-27
AU646163B2 (en) 1994-02-10
CZ213693A3 (en) 1994-05-18
WO1992018507A1 (en) 1992-10-29
FI934461A7 (fi) 1993-10-11
HU9302869D0 (en) 1993-12-28
EP0580812A1 (en) 1994-02-02
IE921148A1 (en) 1992-10-21

Similar Documents

Publication Publication Date Title
JPS6183198A (ja) 新規アミノ酸化合物
US20220098152A1 (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
JPS6317882A (ja) 5−置換−1H−ピラゾロ〔3,4−b〕ピラジン誘導体及び該化合物を含有する抗腫瘍剤
CN104557588B (zh) 咖啡酸和阿魏酸的同二聚体,其制备方法及其药物组合物
CN110092808A (zh) 一种甾醇化合物和药学上可接受的盐或前药及其应用
CN115677828B (zh) 一种抗肿瘤的间二氯苯酚衍生物及其制备方法
JP2022553833A (ja) エストロゲン受容体調節薬の塩及び形態
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
CN105566314B (zh) 一种盐酸替扎尼定化合物
TW201247680A (en) Amorphous N-benzoyl-staurosporine, processes for the preparation, and use thereof
TW385250B (en) Treating agent for diseases due to infection with helicobacter
US3989746A (en) Substituted naphthyl anthranilic acids
CN104860847B (zh) 利凡斯的明和咖啡酸、阿魏酸的二聚体,其制备方法及其药物组合物
JP2018537515A (ja) フェンカンファミンのプロドラッグ
CN106065016A (zh) 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法
JP2022527279A (ja) キノリン誘導体及び癌の治療のためのその使用
JPS6242953A (ja) 1,1,2,2−テトラメチル−1,2−ビス−(フツ素−4−ヒドロキシ−フエニル)−エタンの新規誘導体、その製法およびこれを含有する抗癌剤
US8946474B2 (en) Polymorphic form of a calcimimetic compound
CN102670572A (zh) 一种双-(2,3-二溴-4,5-二羟基苄基)醚的合成与应用
CN104211669B (zh) 含笑内酯衍生物,及其制备方法和用途
CN100569740C (zh) N-or酰胺类化合物,其制备方法和其应用
WO2015010666A2 (zh) 一种苯酚衍生物及其应用
CN102666528A (zh) 晶体cdc7 抑制剂盐
JPS6322069A (ja) 複素多環式芳香族化合物
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида